A newly discovered small molecule could be sprayed into people’s noses to prevent COVID-19 illness prior to exposure and provide early treatment if administered soon after infection, according to a study in mice led by Cornell researchers.
The study, published March 28 in the journal Nature, employed experimental mice engineered with human receptors for the SARS-CoV-2 virus on their cell surfaces and found that a molecule, called N-0385, inhibited entry of the virus into cells in the body. At Cornell, N-0385 was shown to protect mice from infection prior to exposure, while also providing effective treatment when administered up to 12 hours after exposure. The molecule was developed in collaboration with investigators at the Université de Sherbrooke in Quebec, Canada.
The treatment holds promise for both preventing disease and reducing severity of and mortality from COVID-19 post-infection with a few single daily doses.
“There are very few, if any, small molecule antivirals that have been discovered that work prophylactically to prevent infection,” said Hector Aguilar-Carreno, associate professor of virology in the Department of Microbiology and Immunology in the College of Veterinary Medicine, and a senior author of the paper, “A TMPRSS2 Inhibitor ACTS as a pan-SARS-CoV-2 prophylactic and therapeutic.” Other senior authors include Francois Jean, associate professor of microbiology and immunology at the University of British Columbia in Vancouver, and Richard Leduc, professor of pharmacology at the Université de Sherbrooke.
“This is the first of its kind,” Aguilar-Carreno said. “One advantage is that it works early in the infection, even after someone has already acquired the virus.”
The broad-spectrum therapy was tested in mice exposed to the first strain detected in the U.S. in Washington state in 2020, as well as the Delta strain, but has not been tested on the Omicron variant, though the researchers are optimistic it will remain effective.
A California-based company, EBVIA Therapeutics, Inc., is currently raising funds for human trials, drug development, formulation and mass production. If money is raised quickly, and if human trials prove successful, the hope is that the treatment could be submitted for FDA emergency-use approval within a minimum of six months. “The N-0385 therapy is simpler and less expensive to mass produce than other types of COVID-19 treatments, such as monoclonal antibodies,” Aguilar-Carreno said.
Coronaviruses carry a spike protein; in order to infect a cell, features of the spike protein must bind with a receptor on the host cell’s surface. In the study, the researchers targeted an enzyme, TMPRSS2, a type-II transmembrane serine protease. TMPRSS2 plays an essential role in the virus life cycle by cleaving the spike protein to expose a peptide that allows the virus to fuse its surface with a cell’s membrane to gain entry.
The researchers started by identifying candidate small molecules, including N-0385, which they believed would inhibit TMPRSS2’s ability to facilitate the virus’ entry into a cell by blocking where the protease attaches to the spike protein.
They then conducted in vitro tests to see if the small molecules would in turn inhibit SARS-CoV-2 entry into different cell types, including human respiratory cells, which are especially vulnerable to the virus. These tests proved successful.
Aguilar-Carreno’s lab members then tested the treatment in mice engineered with human receptors for the virus on their cells, since lab mice aren’t capable of getting infected with COVID-19. The small molecule was intranasally introduced into the mice before, during, and/or after infection.
They tracked the mice’s weight – as weight loss signals infection and is a good indicator of disease– and other clinical and pathological measurements, such as temperature and mortality, and mouse tissue analysis to understand how well the mice responded. The therapy prevented the mice from losing weight, prior to SARS-CoV-2 exposure, and from dying post infection. Even up to 12 hours after infection, the treatment showed very good efficacy, Aguilar-Carreno said.
Human trials will be the next step, once the funds are raised.
Original Article: Promising nose spray could prevent and treat COVID-19
The Latest on: Covid nose spray
- Why a covid spray could be costlyon August 7, 2022 at 12:00 am
If we are blithely ignorant now of rates of covid-19 infection, it's largely thanks to vaccines, which kept most people free from serious illness.
- German government supports development of nasal COVID-19 vaccineon August 5, 2022 at 2:29 am
The German government will fund the development of a nasal vaccine against COVID-19 similar to flu vaccines already available for children. Since the vaccine is directly applied to the nasal mucosa ...
- Is There a Nasal Spray COVID Vaccine? Researchers Are Working on Iton August 3, 2022 at 10:21 am
It's not available yet, but getting your COVID immunity by way of a nose spray could have benefits, scientists say.
- Your Next COVID Vaccination Could Be a Nasal Spray: Here's Whyon August 2, 2022 at 10:41 am
Scientists are working on a new nasal spray vaccine for COVID-19. Here's why a nasal vaccine may be more effective in fighting the virus.
- A New Kind of COVID Defense: Nasal Spray Vaccineson August 2, 2022 at 5:00 am
It should come as no surprise, then, that scientists are working on a nasal COVID-19 vaccine to stop the disease right where it starts. The current injectable vaccines – including Moderna, Pfizer and ...
- New trial shows nasal spray reduces infection of COVID-causing virus by 62%on August 1, 2022 at 10:31 am
A new clinical trial led by Queen Mary University of London and Barts Health researchers has shown that the pHOXWELL nasal spray can reduce infection with SARS-CoV-2—the virus that causes COVID-19—by ...
- Texas researchers develop COVID nasal vaccineon July 29, 2022 at 3:30 am
The University of Texas Medical Branch (UTMB) in Galveston and the Catholic University of America (CUA) in Washington, D.C. said researchers have developed a COVID-19 vaccine delivered through the ...
- Viewpoints: The Next Covid Vaccine May Be A Nasal Spray; Broader-Protecting Covid Vaccines Neededon July 28, 2022 at 6:13 am
Nose Covid Spray Will Be Costly If we are blithely ignorant now of rates of Covid-19 infection, it’s largely thanks to vaccines, which kept most people free from serious illness. But the immune ...
- Why an Up-Your-Nose Covid Spray Will Be Costlyon July 27, 2022 at 10:10 pm
One option that has many excited are nasal spray vaccines, but there is also reason for caution. Recent research by scientists at the University of Virginia and published in the journal Science ...
- Is the War Against COVID Variants Won in the Nose?on July 25, 2022 at 9:44 am
The best booster for COVID vaccinations might not be yet another shot, but a nasal spray, an early study hints.
via Bing News
The Latest on: Covid nose spray
via Google News